---
layout: post
title: "Gilead Sciences, Inc.; Withdrawal of Approval of Indications for Relapsed Follicular Lymphoma and Relapsed Small Lymphocytic Lymphoma for ZYDELIG (Idelalisib) Tablets"
date: 2026-02-05 18:59:17 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-11277
original_published: 2022-05-26 00:00:00 +0000
significance: 8.00
---

# Gilead Sciences, Inc.; Withdrawal of Approval of Indications for Relapsed Follicular Lymphoma and Relapsed Small Lymphocytic Lymphoma for ZYDELIG (Idelalisib) Tablets

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** May 26, 2022 00:00 UTC
**Document Number:** 2022-11277

## Summary

The Food and Drug Administration (FDA or Agency) is announcing that it is withdrawing approval of the indications for relapsed follicular lymphoma and relapsed small lymphocytic lymphoma for ZYDELIG (idelalisib) Tablets, approved under new drug application (NDA) 205858, held by Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, CA 94404 (Gilead). Gilead voluntarily requested that the Agency withdraw approval of these indications and waived its opportunity for a hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/05/26/2022-11277/gilead-sciences-inc-withdrawal-of-approval-of-indications-for-relapsed-follicular-lymphoma-and)
- API: https://www.federalregister.gov/api/v1/documents/2022-11277

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
